Genenta Science SpA ADR
Yahoo Finance • last year
Genenta to Present at Upcoming Scientific and Investor Conferences
MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a perm... Full story
Yahoo Finance • 2 years ago
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable an... Full story
Yahoo Finance • 2 years ago
Genenta to Provide Update on Lead Product Temferon™
MILAN, Italy and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- Luigi Naldini, Ph.D., M.D., co-founder and Executive Scientific Board Chairman of Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage immuno-oncology company, will be presen... Full story
Yahoo Finance • 2 years ago
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
Funds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025Net exchange rate gain of €2.3 millionTax credit of €6.4 million MILAN, Italy and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Ge... Full story
Yahoo Finance • 2 years ago
Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications
MILAN, Italy and NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable a... Full story
Yahoo Finance • 2 years ago
Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement
MILAN, N.Y., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a dev... Full story
Yahoo Finance • 2 years ago
Genenta Provides First Half 2022 Business Update and Financial Results
Current dose escalation study data shows a median overall survival of 17 months Adding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimenCash and cash equivalents of €34.7 million as of June 30, 2022, providing a c... Full story
Yahoo Finance • 2 years ago
AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative
MILAN, Italy, July 25, 2022 (GLOBE NEWSWIRE) -- Bowling Green Bull (BGB) is an initiative to connect Italian companies, entrepreneurs and top managers aiming for international growth and expansion in their interactions with U.S. financia... Full story
Yahoo Finance • 3 years ago
Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA
MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will be p... Full story
Yahoo Finance • 3 years ago
Genenta Appoints Industry Veteran Tim Obara as Head of Business Development
MILAN, Italy and NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces... Full story
Yahoo Finance • 3 years ago
Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme
No dose limiting toxicity observed in previous three dose level cohorts Represents a 50% higher dose than highest prior level Update of guidance for trial MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NA... Full story
Yahoo Finance • 3 years ago
Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma
MILAN, Italy and NEW YORK, May 02, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces... Full story
Yahoo Finance • 3 years ago
Genenta Announces Nomination of Mark A. Sirgo as Chair
35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage... Full story
Yahoo Finance • 3 years ago
Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors
MILAN, Italy and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announc... Full story
